SCHEDULE: Soleus Capital Discloses CalciMedica Stake

Soleus Capital and affiliated entities report a 2.4% beneficial ownership stake in CalciMedica, Inc. through warrant holdings.

Summary

• Soleus Capital Management, L.P. and its affiliates, led by Guy Levy, have filed a Schedule 13G indicating beneficial ownership of 391,952 shares of CalciMedica, Inc. common stock.
• The reported ownership consists entirely of presently exercisable warrants to purchase common stock.
• The aggregate ownership represents approximately 2.4% of the company's outstanding common stock, based on 15,743,916 shares outstanding as of February 25, 2026.
• The filing confirms that these securities were acquired for investment purposes and not to influence or change control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing. It represents standard disclosure of existing holdings and does not signal a change in the company's fundamental outlook or strategic direction.

Positives

• Institutional investment firm maintains a position in the company, signaling continued interest in the issuer's equity.
• The filing confirms the reporting persons do not intend to seek control of the company, reducing the likelihood of immediate activist-driven volatility.

Negatives

• The reported stake is relatively small at 2.4%, which does not constitute a significant controlling interest.
• The entire position is comprised of warrants rather than direct common stock ownership, indicating a derivative-based exposure.

Risks

• The value of the investment is tied to the exercise of warrants, which are subject to the underlying performance and market price of the common stock.
• The reporting persons disclaim beneficial ownership for purposes other than Section 13(d) compliance, highlighting the complex structure of the investment vehicles.

Future Outlook

The reporting persons state that the securities were acquired for investment purposes and they do not currently intend to change or influence the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for institutional investors. It reflects typical portfolio management activity within the biotechnology sector, where firms often hold warrants as part of broader investment strategies in small-cap companies.

Comparison to Industry Standards

• The 2.4% stake is consistent with passive institutional investment patterns in the small-cap biotech space.
• The use of warrants as a primary investment vehicle is common for private equity and hedge funds participating in biotech financing rounds.

Stakeholder Impact

• Shareholders should note the continued presence of institutional investors in the company's capital structure.

Next Steps

• The reporting persons will continue to monitor their investment in the issuer.

Key Dates

Keywords

CalciMedica, Schedule 13G, Soleus Capital, Warrants, Institutional Ownership, Guy Levy